ESC 24: Hot Line & Late-breaking Science Video Collection
-
8m 18sPart 4 | Session 5 STEEER-AF: Stroke Prevention & Rhythm Control Therapy
-
3m 52sPart 4 | Session 6 NOTION-3: FFR Guided PCI in TAVI
-
6m 48sPart 4 | Session 7 EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
-
8m 17sPart 4 | Session 8 SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI
-
3m 51sPart 4 | Session 9 EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients
-
4m 17sPart 4 | Session 10 SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes
-
4m 17sPart 4 | Session 11 GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals
-
2m 31s
-
7m 9sPart 4 | Session 13 POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI
-
4m 54sPart 5 | Session 1 3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan
-
13m 47sPart 5 | Session 2 3 Trials That Will Change My Practice With Dr Michelle Kittleson
-
6m 55sPart 6 | Session 1 New Guidelines for the Management of Atrial Fibrillation
-
6m 13sPart 6 | Session 2 New Guidelines for the Management of Aortic Diseases
-
47m 31sPart 1 | Session 1 ESC Congress 2024 Hot Line Wrap Up
-
27m 27sPart 1 | Session 2 ESC Congress 2024 Hot Line Preview
-
17m 25sPart 2 | Session 1 ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT
-
23m 2sPart 2 | Session 2 ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More
-
12m 28sPart 2 | Session 3 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi
-
15m 45sPart 2 | Session 4 Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More
-
20m 58sPart 3 | Session 1 AβYSS: Beta Blocker Interruption After Uncomplicated MI
-
20m 14sPart 3 | Session 2 RHEIA: TAVR vs SAVR in Women with Severe AS
-
8m 47sPart 3 | Session 3 OCEANIC-AF: Asundexian Vs Apixaban in Atrial Fibrillation
-
9m 29sPart 3 | Session 4 SWEDEGRAFT: No-touch Vein Graft in CABG
-
17m 28sPart 3 | Session 5 FINEARTS-HF: Finerenone HFmEF & HFpEF
-
6m 8s
-
5m 29sPart 4 | Session 2 MATTERHORN: M-TEER vs Surgery in Heart Failure
-
5m 46sPart 4 | Session 3 MRAs in Heart Failure
ESC Congress 2024 — Finerenone improved outcomes in two trials in patients with CKD with T2D, and in patients with HFmrEF and HFpEF.
Investigator, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) joins us in London to discuss the findings from the FINE-HEART pooled analysis (Bayer).
FINE-HEART is a pre-specified, exploratory pooled analysis combining data from three phase III clinical trials evaluating finerenone, a mineralocorticoid receptor antagonist (MRA). The study aimed to assess finerenone's impact on cardiovascular and renal outcomes in a diverse patient population of over 19,000 individuals with varying degrees of heart failure, chronic kidney disease, and type 2 diabetes.
Evidence shows that finerenone could be useful in broad, high-risk patient populations with overlapping cardio-kidney-metabolic conditions.
Interview Questions:
- What is the importance of the study?
- What is the study design, patient cohort and outcome measures?
- What are the key findings?
- Were there any unexpected or surprising findings?
- What are the take-home messages?
- What are the next steps?
Recorded on-site at ESC Congress 2024, London.
Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
What's hot at the ESC Congress 2024?
Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
- Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.
Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at ESC 24?
Part 2
Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Part 6
Guidelines
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.
Comments